A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease

Exclusion Criteria

• •Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal) at Visit 1.
• •Be diagnosed with ocular rosacea, or any viral or bacterial disease of the cornea or conjunctiva, within the last 12 months.
• •Have any planned ocular and/or lid surgeries over the study period.
• •Have corrected visual acuity greater than or equal to +0.7 as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit .
• •Have an uncontrolled systemic disease.
• •Be a woman who is pregnant, nursing or planning a pregnancy.
• •Be a woman of childbearing potential who is not using an acceptable means of birth control
• •Have a known allergy and/or sensitivity to the test article or its components.
• •Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study
• •Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days of Visit 1 Be unable or unwilling to follow instructions, including participation in all study assessments and visits